Kali Zhou1, Norah A Terrault2. 1. Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, California. 2. Division of Gastroenterology and Liver Diseases, Department of Medicine, University of Southern California, Los Angeles, California. Electronic address: Terrault@usc.edu.
Abstract
BACKGROUND & AIMS: The benefits of highly effective therapies for chronic hepatitis B virus (HBV) or HCV infection can only be realized if infected individuals are identified and linked to care. We sought to identify gaps in awareness of diagnosis of HBV or HCV infection in a population-based sample of adults living in the United States (US). METHODS: Using National Health and Nutrition Examinations Surveys data, we examined factors associated with HBV and HCV awareness. Participants surveyed from 2013 through 2016, age ≥20 years, with complete serologic analyses were included. HBV and HCV infections were defined by detection of serum HBsAg and anti-HCV, respectively. The primary outcome was awareness of infection-if participants replied "yes" to the question: "Has a doctor or other health professional ever told you that you have hepatitis B or C?" RESULTS: Of 14,745 participants, 68 had HBV and 211 had HCV infection, corresponding to prevalence values of 0.7% and 1.8%, respectively. Among HBV-infected persons, 32% reported awareness, and 28% of aware persons reported treatment. Among HCV-infected persons, 49% reported awareness, 45% of aware persons were treated, and 59% of treated patients achieved a sustained virologic response. Factors associated with greater awareness in multivariable models included US citizenship, higher education, and abnormal level of alanine aminotransferase for HBV-infected participants and non-Hispanic race, income above the poverty line, not married, and history of injection drug use for HCV-infected participants. CONCLUSIONS: Fewer than half of US adults with HBV or HCV infection are aware of their infection. Opportunities to increase awareness include provider education on cut-off values for abnormal level of alanine aminotransferase that should prompt screening, and expansion of existing screening interventions to under-recognized at-risk groups.
BACKGROUND & AIMS: The benefits of highly effective therapies for chronic hepatitis B virus (HBV) or HCV infection can only be realized if infected individuals are identified and linked to care. We sought to identify gaps in awareness of diagnosis of HBV or HCV infection in a population-based sample of adults living in the United States (US). METHODS: Using National Health and Nutrition Examinations Surveys data, we examined factors associated with HBV and HCV awareness. Participants surveyed from 2013 through 2016, age ≥20 years, with complete serologic analyses were included. HBV and HCV infections were defined by detection of serum HBsAg and anti-HCV, respectively. The primary outcome was awareness of infection-if participants replied "yes" to the question: "Has a doctor or other health professional ever told you that you have hepatitis B or C?" RESULTS: Of 14,745 participants, 68 had HBV and 211 had HCV infection, corresponding to prevalence values of 0.7% and 1.8%, respectively. Among HBV-infectedpersons, 32% reported awareness, and 28% of aware persons reported treatment. Among HCV-infectedpersons, 49% reported awareness, 45% of aware persons were treated, and 59% of treated patients achieved a sustained virologic response. Factors associated with greater awareness in multivariable models included US citizenship, higher education, and abnormal level of alanine aminotransferase for HBV-infectedparticipants and non-Hispanic race, income above the poverty line, not married, and history of injection drug use for HCV-infectedparticipants. CONCLUSIONS: Fewer than half of US adults with HBV or HCV infection are aware of their infection. Opportunities to increase awareness include provider education on cut-off values for abnormal level of alanine aminotransferase that should prompt screening, and expansion of existing screening interventions to under-recognized at-risk groups.
Authors: P Todd Korthuis; Daniel J Feaster; Zoilyn L Gomez; Moupali Das; Susan Tross; Katharina Wiest; Antoine Douaihy; Raul N Mandler; James L Sorensen; Grant Colfax; Dennis McCarty; Stephanie E Cohen; Patricia E Penn; Diane Lape; Lisa R Metsch Journal: Addict Behav Date: 2011-12-14 Impact factor: 3.913
Authors: Stephen C Ko; Lin Fan; Emily A Smith; Nancy Fenlon; Alaya K Koneru; Trudy V Murphy Journal: J Pediatric Infect Dis Soc Date: 2014-12-18 Impact factor: 3.164
Authors: A M Di Bisceglie; M Lombardero; J Teckman; L Roberts; H L A Janssen; S H Belle; J H Hoofnagle Journal: J Viral Hepat Date: 2016-12-05 Impact factor: 3.728
Authors: James W Galbraith; John P Donnelly; Ricardo A Franco; Edgar T Overton; Joel B Rodgers; Henry E Wang Journal: Clin Infect Dis Date: 2014-06-09 Impact factor: 9.079
Authors: Mandana Khalili; Nicole J Kim; Janice Y Tsoh; Judith M E Walsh; L Elizabeth Goldman; Ginny Gildengorin; Ching Wong; Mi T Tran; Edgar Yu; Michael Thanh Sharp; Vivian H LeTran; Vi-Van Nguyen; Tung T Nguyen Journal: J Gen Intern Med Date: 2022-01-06 Impact factor: 6.473
Authors: Lisa R Metsch; Daniel J Feaster; Lauren K Gooden; Carmen Masson; David C Perlman; Mamta K Jain; Tim Matheson; C Mindy Nelson; Petra Jacobs; Susan Tross; Louise Haynes; Gregory M Lucas; Jonathan A Colasanti; Allan Rodriguez; Mari-Lynn Drainoni; Georgina Osorio; Ank E Nijhawan; Jeffrey M Jacobson; Meg Sullivan; David Metzger; Pamela Vergara-Rodriguez; Ronald Lubelchek; Rui Duan; Jacob N Batycki; Abigail G Matthews; Felipe Munoz; Eve Jelstrom; Raul Mandler; Carlos Del Rio Journal: Open Forum Infect Dis Date: 2021-06-27 Impact factor: 4.423
Authors: Bertha E Flores; Andrea A Fernandez; Chen-Pin Wang; Raudel Bobadilla; Ludivina Hernandez; Mamta K Jain; Barbara J Turner Journal: J Cancer Educ Date: 2022-02 Impact factor: 2.037
Authors: Arpan A Patel; Aileen Bui; Eian Prohl; Debika Bhattacharya; Su Wang; Andrea D Branch; Ponni V Perumalswami Journal: Hepatol Commun Date: 2020-12-07